1,429 Shares in Vertex Pharmaceuticals Incorporated (VRTX) Acquired by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,429 shares of the pharmaceutical company’s stock, valued at approximately $263,000.

Several other hedge funds have also recently bought and sold shares of the stock. Resources Investment Advisors Inc. acquired a new position in Vertex Pharmaceuticals during the 4th quarter worth $27,000. Oregon Public Employees Retirement Fund grew its stake in Vertex Pharmaceuticals by 16,530.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock worth $28,000 after purchasing an additional 4,583,156 shares in the last quarter. We Are One Seven LLC acquired a new position in Vertex Pharmaceuticals during the 4th quarter worth $32,000. Berman Capital Advisors LLC acquired a new position in Vertex Pharmaceuticals during the 4th quarter worth $35,000. Finally, Sontag Advisory LLC acquired a new position in Vertex Pharmaceuticals during the 4th quarter worth $36,000. Hedge funds and other institutional investors own 95.02% of the company’s stock.

In other news, SVP Paul M. Silva sold 2,812 shares of the company’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $186.97, for a total transaction of $525,759.64. Following the completion of the transaction, the senior vice president now directly owns 18,903 shares of the company’s stock, valued at approximately $3,534,293.91. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP David Altshuler sold 5,624 shares of the company’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $187.00, for a total value of $1,051,688.00. Following the transaction, the executive vice president now directly owns 32,604 shares of the company’s stock, valued at $6,096,948. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 81,705 shares of company stock valued at $14,703,196. Insiders own 0.75% of the company’s stock.



NASDAQ:VRTX opened at $164.61 on Tuesday. The stock has a market cap of $42.16 billion, a PE ratio of 58.17, a price-to-earnings-growth ratio of 2.47 and a beta of 1.56. Vertex Pharmaceuticals Incorporated has a 1 year low of $144.07 and a 1 year high of $195.81. The company has a quick ratio of 3.66, a current ratio of 3.78 and a debt-to-equity ratio of 0.13.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.49. The business had revenue of $857.00 million during the quarter, compared to analysts’ expectations of $853.00 million. Vertex Pharmaceuticals had a return on equity of 22.63% and a net margin of 66.01%. The business’s quarterly revenue was up 34.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.76 EPS. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 3.06 earnings per share for the current year.

Several research analysts recently commented on VRTX shares. BidaskClub raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 16th. Cowen reissued a “buy” rating and set a $220.00 target price on shares of Vertex Pharmaceuticals in a research note on Wednesday, March 6th. JPMorgan Chase & Co. reissued a “buy” rating and set a $209.00 target price on shares of Vertex Pharmaceuticals in a research note on Wednesday, May 1st. Needham & Company LLC reissued a “buy” rating and set a $195.00 target price on shares of Vertex Pharmaceuticals in a research note on Wednesday, May 1st. Finally, ValuEngine raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fifteen have given a buy rating to the stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and an average target price of $203.35.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://dakotafinancialnews.com/2019/05/14/1429-shares-in-vertex-pharmaceuticals-incorporated-vrtx-acquired-by-mercer-global-advisors-inc-adv.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Featured Story: Stock Split

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.